Pharma Segment Growth
The pharma segment achieved 8% core sales growth and an adjusted EBITDA margin of approximately 35%. Growth was driven by increased sales of higher value products and royalties.
Active Material Science Sales Increase
Active material science sales were up 13% for the full year 2024, due to increased demand for diabetes diagnostics, probiotics, and oral solid dose solutions.
Closure Segment Improvement
The closures segment returned to its core sales long-term target range, improving plant utilization by over 12% and achieving a 110 basis point improvement in adjusted EBITDA margins.
Record Return to Shareholders
Returned nearly $800 million to shareholders over five years through dividends and share repurchases, with 2025 expected to mark the 32nd consecutive year of increasing dividends.
Sustainability and Recognition
AptarGroup secured a place on the Climate A List and was named one of the World's Top Companies for Women by Forbes for the fourth consecutive year.